



MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3

July 20, 2022

MARIETTA, Ga., July 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced that it will report operating and financial results for the second quarter ended June 30, 2022, after the market close on Tuesday, August 2, 2022. The MIMEDX senior management team will host a webcast and conference call to review its results on Wednesday, August 3, 2022, beginning at 8:30 a.m. Eastern Time.

The conference call can be accessed using the following information:

Webcast: [Click here](#)

U.S. Investors: 877-407-6184

International Investors: 201-389-0877

Conference ID: 13730760

A replay of the webcast will be available for approximately 30 days on the Company's website at www.mimedx.com following the conclusion of the event.

About MIMEDX

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contacts:

Investors

Jack Howarth

404-360-5681

jhowarth@mimedx.com

Corporate Communications

Hilary Dixon

404-323-4779

hdixon@mimedx.com